Patents by Inventor Kirk McMullin

Kirk McMullin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10166686
    Abstract: A portable, self-contained, ready-to-use, sterile enclosure used in the filling of small quantities of sterile products. Particularly, an enclosure that contains the vials or bottles to be filled, as well as all necessary fittings and filters integrated with the assembled apparatus, and which as a total assembly can be reduced to a small package size, thereby enabling the entire assembly to be sterilized remotely in one step by gamma irradiation or ethylene oxide gas. The design of the enclosure assembly further enables shipment to the end user in sterile ready-to-use condition, and allows the end user to perform sterile filling within the enclosure without the need for any aseptic connections or further equipment sterilization steps.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 1, 2019
    Inventors: Jasbir Dhanjal, Kirk McMullin
  • Patent number: 8748402
    Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: June 10, 2014
    Assignee: Bausch & Lomb Pharma Holdings Corp.
    Inventors: Mark Abelson, Kirk McMullin, Angel Padilla
  • Patent number: 8372814
    Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: February 12, 2013
    Assignee: ISTA Pharmaceuticals, Inc.
    Inventors: Mark Abelson, Kirk McMullin
  • Publication number: 20120195972
    Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 2, 2012
    Applicant: ISTA Pharmaceuticals, Inc.
    Inventors: Mark Abelson, Kirk McMullin, Angel Padilla